Novanta sees FY25 adjusted EPS $3.35-$3.55, consensus $3.79

Sees FY25 revenue $1B, consensus $1.04B. “We continue to see strength in our medical business and reconfirm our outlook for incremental new product sales in 2025, the majority of which sell into hospital operating room and surgical equipment,” said Matthijs Glastra. “Although capital spending in industrial, semiconductor, and life science is expected to remain volatile in the first half of the year due to trade war uncertainty, government funding, and geopolitical disruptions, there continues to be strong signs of growth slowly recovering. While we are optimistic about stronger revenue growth in these markets, our initial full-year guidance will remain conservative until these growth trends strengthen. Therefore, our full year revenue guidance is based on delivering $50 million of incremental new product sales, primarily in the medical technology markets, and presumes no market recoveries in the capital spending markets in industrial, semiconductor, and life science at this time.”